Bibliographic details
Cromwell I, van der Hoek K, Melosky B, Peacock S. Erlotinib or docetaxel for second-line treatment of non-small cell lung cancer: a real-world cost-effectiveness analysis. Journal of Thoracic Oncology 2011; 6(12): 2097-2103
MeSH
Adult; Aged; Aged, 80 and over; Antineoplastic Agents /economics /therapeutic use; British Columbia; Carcinoma, Non-Small-Cell Lung /drug therapy; Chi-Square Distribution; Cost-Benefit Analysis; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms /drug therapy; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors /economics /therapeutic use; Quinazolines /economics /therapeutic use; Retrospective Studies; Taxoids /economics /therapeutic use